Insulin dose adjustment policy for certified diabetes care and education specialists: Safe and effective
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Certified Diabetes Care and Education Specialists (CDCES) safely adjusted insulin doses for youth with new-onset type 1 diabetes using remote continuous glucose monitor (CGM) data. This protocol improved patient outcomes and can be adopted by other centers.
Area Of Science
- Pediatric Endocrinology
- Diabetes Technology
- Clinical Protocol Development
Background
- Youth with new-onset type 1 diabetes require intensive management for optimal glycemic control.
- Continuous glucose monitoring (CGM) provides valuable data for diabetes management.
- Remote patient monitoring and specialist intervention can enhance diabetes care delivery.
Purpose Of The Study
- To describe and evaluate a protocol for Certified Diabetes Care and Education Specialists (CDCES) to make remote insulin dose adjustments for youth with new-onset type 1 diabetes using CGM data.
- To assess the safety and effectiveness of CDCES-led insulin dose adjustments in achieving glycemic targets.
- To provide a data-supported protocol for broader adoption in diabetes centers.
Main Methods
- A protocol was established for CDCES to adjust insulin doses based on CGM data and patient information, with consultation from Pediatric Endocrinologists.
- Remote CGM data was reviewed, and dose adjustments and behavioral recommendations were communicated via secure portal messaging.
- 133 participants with new-onset type 1 diabetes were monitored remotely, with 1564 messages exchanged in the first year.
Main Results
- The majority of remote messages were triggered by low time-in-range (TIR), hypoglycemia, declining TIR, or insufficient CGM wear.
- There were 3 episodes of severe hypoglycemia, none adjudicated as related to the CDCES dosing protocol.
- At one year, mean time <70 mg/dl was <2%, and 64% of participants achieved an A1C target of <7%.
Conclusions
- A CDCES-led protocol for remote insulin dose adjustment is safe and effective in managing new-onset type 1 diabetes in youth.
- CDCESs can operate at the top of their certification to improve patient outcomes through proactive diabetes management.
- This protocol facilitates increased patient-provider interaction and can be implemented in other diabetes centers.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...